The safety of vedolizumab for ulcerative colitis and Crohn's disease. [electronic resource]
Producer: 20170710Description: 839-851 p. digitalISSN:- 1468-3288
- Adrenal Cortex Hormones -- therapeutic use
- Adult
- Age Factors
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antibodies, Neutralizing -- blood
- Chemical and Drug Induced Liver Injury -- epidemiology
- Clostridium Infections -- epidemiology
- Colitis, Ulcerative -- drug therapy
- Crohn Disease -- drug therapy
- Female
- Gastrointestinal Agents -- adverse effects
- Humans
- Incidence
- Infusions, Intravenous -- adverse effects
- Leukoencephalopathy, Progressive Multifocal -- epidemiology
- Male
- Middle Aged
- Narcotics -- therapeutic use
- Neoplasms -- epidemiology
- Randomized Controlled Trials as Topic
- Risk Factors
- Sepsis -- epidemiology
- Treatment Failure
- Tuberculosis -- epidemiology
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.